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We demonstrate a high-throughput biosensing device that utilizes microfluidics based plasmonic
microarrays incorporated with dual-color on-chip imaging toward real-time and label-free monitoring of
biomolecular interactions over a wide field-of-view of.20 mm2.Weighing 40 grams with 8.8 cm in height,
this biosensor utilizes an opto-electronic imager chip to record the diffraction patterns of plasmonic
nanoapertures embedded within microfluidic channels, enabling real-time analyte exchange. This
plasmonic chip is simultaneously illuminated by two different light-emitting-diodes that are spectrally
located at the right and left sides of the plasmonic resonance mode, yielding two different diffraction
patterns for each nanoaperture array. Refractive index changes of themedium surrounding the near-field of
the nanostructures, e.g., due tomolecular binding events, induce a frequency shift in the plasmonicmodes of
the nanoaperture array, causing a signal enhancement in one of the diffraction patterns while suppressing
the other. Based on ratiometric analysis of these diffraction images acquired at the detector-array, we
demonstrate the proof-of-concept of this biosensor bymonitoring in real-time biomolecular interactions of
protein A/G with immunoglobulin G (IgG) antibody. For high-throughput on-chip fabrication of these
biosensors, we also introduce a deep ultra-violet lithography technique to simultaneously pattern thousands
of plasmonic arrays in a cost-effective manner.
C
ompact and light-weight diagnostic devices hold significant promise for early detection andmonitoring of
diseases in field settings. Such point of care tools1 aim to replace bulky equipment that are frequently used
in medical labs, which can potentially enable decentralized biomedical testing and diagnosis in both
developed and developing parts of the world. These field-deployable devices can be used as optical biosensors2–4
through labelling methods or label-free techniques to detect e.g., nucleic acids, proteins and pathogens in field
conditions. For instance, fluorescence labelling has been widely employed as a read-out mechanism in various
biochemical assays; however, the intricate sample preparation procedures pose certain challenges on field use of
such fluorescence based diagnostic technologies. Therefore, label-free detection approaches5 provide simple and
rapid biosensing devices that can be used for sensitive and specific detection of biomolecular interactions. These
label-free platforms should ideally be able to monitor multiple biomarkers simultaneously for accurate diagnosis
of diseases, which necessitates high-throughput screening techniques. Towards this end, there has been consid-
erable effort to develop high-throughput label-free sensors utilizing surface plasmon resonance (SPR)6, photonic
crystals7, optical micro-cavities8, interferometry9, as well as nanostructured metal substrates, e.g., subwavelength
nanohole arrays10, among others. Despite their high performance sensing and biodetection potential, most of
these techniques are based on benchtop instruments, which constrains their use in remote and field settings.
Thus, there is an emerging need to devise field-portable forms of these biosensors to achieve high-throughput
detection without the use of any labels11. Along these lines, we have recently introduced a handheld plasmonic
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biosensing device12 that merges on-chip imaging and nanohole
arrays towards detection of ultrathin protein layers, which might
find use in field deployable sensing applications.
In this work, as an improved solution to this important need, we
demonstrate a microfluidics based plasmonic biosensing system that
integrates plasmonic microarrays with dual-color lensfree imaging
for real-time and multiplexed monitoring of binding events over a
wide field-of-view of larger than 20 mm2 in low resource settings. In
this platform (see Figs. 1a and 1b), we utilize an opto-electronic
sensor (Complementary Metal–Oxide–Semiconductor - CMOS) to
record the diffraction patterns of plasmonic nano-apertures located
at the bottom of a microfluidic channel (see the photograph in
Fig. 1c), enabling controlled delivery of target solution to the surface
functionalized nanosensor arrays (see the Methods section for dual-
color lensfree imaging set-up). As illustrated in Fig. 1d, the target
proteins are captured on the plasmonic pixels that are functionalized
by the ligand proteins. In our biosensing platform, the use of a
plasmonic nanohole array provides high sensitivities to surface con-
ditions due to the strong light confinements and high field enhance-
ments at nanoscale13–15. Changes in the refractive index within the
proximity of the sensor surface induce a spectral shift in the peak
wavelength of the plasmonic mode supported by the nanohole array.
We have recently investigated the use of such nanohole arrays for
biosensing applications including detection of proteins and infectious
viruses from biological media14,15. The shift in the peak wavelength of
the plasmonic mode can also be determined over large areas using a
CMOS or a CCD (Charge-Coupled Device) based imager16 when the
nanostructures are excited using an illumination source, e.g., a light
emitting diode (LED) with a spectrum tuned to the plasmonic mode
of the nanohole array.
Compared to spectrometer-based analysis of plasmonic sub-
strates, the use of a lensfree on-chip imager as a biosensing approach
to probe the plasmonic mode offers higher multiplexing capability,
where multiple plasmonic nanostructures can be analysed simulta-
neously rather than measuring each plasmonic structure sequen-
tially. The merge of microfluidics17 with plasmonic detection and
lensfree imaging also provides various advantages: (i) The sample
preparation (collection and processing of target analytes) can be
integrated with the plasmonic detection on the same platform, cre-
ating an automated biosensing tool for field use. (ii) The precise
delivery of analytes to the plasmonic substrate improves the sensitiv-
ity and detection limit of the plasmonic biosensor. (iii) The ability to
deliver the sample onto the plasmonic substrate over time allows
rapid monitoring of binding events without the need for any labels.
(iv) The sample exchange with fluidic injection and withdrawal also
increases the multiplexing capability of the biosensing platform,
where multiple analytes can be monitored over a wide range of con-
centrations on the same substrate (see the Methods section and
Supplementary Fig. 1 for the structure of the microfluidic chamber
design).
The plasmonic substrate utilized in our biosensor platform, con-
taining arrays of plasmonic pixels, is simultaneously illuminated by
two different color LEDs (Fig. 1a inset shows the photograph of the
LEDs, at 820 nm and 880 nm, respectively) tuned spectrally to the
right and left sides of the plasmonic mode (see Fig. 2a). The two
resulting diffraction patterns for each plasmonic pixel are recorded
by the CMOS detector as schematically illustrated in Fig. 2c. For our
image analysis, we utilize the configuration where the center-to-cen-
ter distance between two LED sources is D 5 11 mm (see
Supplementary Fig. 2 for diffraction pattern positions for different
LED separation distances). These lensfree diffraction patterns can be
numerically estimated using a spatial convolution and the Fresnel
kernel approach, as detailed in our previous work12 (also see Supple-
mentary Fig. 3 for the details of transmission calculations for our dual
LED configuration). Briefly, the local electromagnetic field distri-
bution determined by finite difference time domain (FDTD) simu-
lation at the plasmonic chip surface is first transformed from the
spatial domain into the frequency space, next propagated over a
vertical distance of 2 mm, and finally transferred back to the spatial
domain to determine the diffraction pattern where the CMOS active
area is present. The refractive index change of the medium covering
the plasmonic nanostructures shifts the plasmonic modes such that
the total transmission signal in the diffraction patterns of the nano-
hole arrays varies. Fig. 2b exemplifies this fact by monitoring the
change in the plasmonic pixels under DI-water (n 5 1.3330) and
sucrose solution of 1.1 mol/L (n5 1.3860). As the refractive index of
Figure 1 | Microfluidics based high-throughput plasmonic biosensing platform using dual-color lensfree on-chip imaging configuration.
(a) Photograph of the on-chip sensing device that employs a plasmonic substrate located at the bottomof amicrofluidic channel. Figure Inset: The head of
the lensfree device that contains two spectrally different LEDs (with 820 nm and 880 nm peak wavelengths) for simultaneous illumination of the
microfluidic chip. (b) Schematics of the on-chip biosensing device composed of a battery, two LEDs, a plasmonic chip, a microfluidic chamber, and a
CMOS imager chip. (c) Photograph of the microfluidic system with inlet and outlet ports. (d) Schematic illustration of the flow-over scheme for delivery
of target samples to the plasmonic substrate.
www.nature.com/scientificreports
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the bulk solution increases, the plasmonic mode shifts to longer
wavelengths from 852 nm to 878 nm, as shown in Fig. 2a. Hence,
the intensity of the diffraction pattern of the nanohole arrays formed
by the LED illumination at 820 nm decreases, whereas it increases at
880 nm illumination. The ratio of these two transmitted signals
obtained from one plasmonic pixel is used to increase the image
contrast resulting from the spectral shift of the plasmonic mode.
This ratiometric analysis that is enabled with a dual-color LED illu-
mination configuration offers more robust and reliable spectral vari-
ation information compared to a single LED illumination10,12 (see the
Methods section).
For field-settings and point-of-care applications, it is important to
reduce the cost of the consumables including the sensor chip.
Toward this goal, we introduce a new fabrication method based on
deep ultra-violet (UV) lithography (see Fig. 3d for the illustration of
the fabrication process) that can create thousands of high fidelity
plasmonic biosensor pixels at low cost, which is highly important
for field applications. Compared to the fabrication of plasmonic
chips using conventional Electron Beam Lithography, which is
sequentially performed on each chip, we perform deep UV litho-
graphy at wafer scale within less than a minute of exposition time,
followed by standard fabrication procedures (see the Methods sec-
tion for the details of the fabrication method). Our fabrication
method is highly flexible such that plasmonic sensor chips with
different designs employing various sensor pixel numbers, sizes or
spatial arrangements can be conveniently manufactured. For this
work, on a 4-inch wafer (see Fig. 3a), we fabricated more than 50
plasmonic sensor chips with 1 cm 3 1 cm dimension (see Fig. 3b),
where each chip covers 8 square membranes/pixels with 100 mm 3
100 mmdimension containing approximately 28,000 nanoapertures.
Fig. 3c shows the scanning electron microscope (SEM) image of the
sensor chip, demonstrating the uniformity of the nanoapertures
achieved by our fabrication method.
Results and Discussion
To evaluate the sensitivity of our biosensing platform, we performed
quantitative concentration experiments using sugar solutions with
known refractive indices (see the Methods section for sensitivity
analysis) within the microfluidic channels that uniformly cover our
plasmonic substrates. The results presented in Fig. 4a demonstrate
that the increase in the sucrose concentration from 0.055 to 1.1 mol/L
causes the plasmonic mode to red shift, which is measured by a
spectrometer for comparison purposes (see the Methods section).
For this sugar concentration range, the amount of peak wavelength
shift varies from 1.26 nm to 31.34 nm, which corresponds to a
change in the bulk refractive index from 1.3356 to 1.3860. Fig. 4b
shows the statistical analysis of this peak wavelength of the plasmo-
nic mode supported by the nanohole array embedded in DI-water
and the sucrose solutions at different concentrations. Fig. 4c demon-
strates the corresponding relative intensity ratios (IRs) determined
from our dual-wavelength lensfree images for each sample. These
results exhibit a high correlation between the wavelength shift
information (acquired by a spectrometer) and the ratiometric ana-
lysis of our dual-wavelength lensfree diffraction images. In the lens-
Figure 2 | Operation principles of dual-wavelength plasmonic detection platform. (a) Solid curves: Spectral variation in the plasmonic mode
supported by the nanohole arrays under DI-water and sucrose solution 1.1 M. Filled curves: The spectral responses of the two LEDs employed by the
lensfree on-chip imaging platformwith peakwavelengths of 820 nmand 880 nm. (b) 3D visualization of the intensity of the dual diffraction pattern of the
nanohole arrays formed by LED illuminations at 820 nm and 880 nm under DI-water and sucrose solution, respectively. Figure inset: Raw lensfree dual
diffraction image for a single plasmonic pixel. (c) Schematic illustration of the generation of dual-diffraction patterns at the detector plane of the lensfree
platform. LED separation distance: D, dual diffraction pattern separation distance: d, LED to plasmonic chip: h1, and plasmonic chip to on-chip
imager active area: h2.
www.nature.com/scientificreports
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free detection approach, a minimum detectable IR of 1.31 (a.u.)
(indicated by a red line in Fig. 4c) has been calculated by adding
twice the standard deviation to the mean intensity ratio value of the
reference sensor (response of the nanohole array under DI-water).
This IR value (1.31) corresponds to a minimum detectable wave-
length shift of 1.5 nm, denoted by a red line in Fig. 4b, which is
equivalent to a minimum detectable refractive index change of,2 3
1023 RIU calculated using a refractive index sensitivity (RIS) of
621 nm/RIU (see the Methods section for refractive index sensitivity
analysis using an optical spectrum analyzer). For the lensfree detec-
tion scheme that is based on diffraction pattern intensity changes,
the minimum detectable relative intensity ratio is obtained as
0.01881, which corresponds to a minimum detectable refractive
index change of ,1 3 1023 RIU, calculated using a RIS of
17.53924/RIU (see the Methods section for our refractive index sens-
itivity analysis). These results suggest that the presented dual color
biosensing platform that is integrated with microfluidics yields more
than two fold improvement in the detection limit compared to our
earlier single color lensfree detection design12. This sensitivity
enhancement is attributed to our ratiometric analysis based on
dual-wavelength illumination that digitally improves the detectable
differences of refractive index changes occurring in the near-field of
our plasmonic substrate.
In our biosensing device, as we utilize a microfluidic chip inte-
grated with an imaging based platform, we can perform high-
throughput analysis of protein-protein binding kinetics. Through a
ratiometric digital analysis based on the dual-wavelength diffraction
images, we can quantify the biomolecular interactions, revealing the
real-time binding analysis of protein-protein complexes. For proof of
concept demonstration, we utilize protein A/G and IgG antibody (see
the Methods section for the details of our protein detection experi-
ments), where we performed time lapse measurements within the
microfluidic channels to detect their affinity as schematically illu-
strated in Fig. 5a. In Fig. 5, we demonstrate the association phase
results for protein IgG (200 mg/mL) onto protein A/G (100 mg/mL)
over 80minutes of injection time. In this phase, the binding events of
IgG to A/G result in an exponential increase in the peak wavelength
shift as well as in the intensity ratio curve, leading to the saturation of
our plasmonic sensor response since the binding sites on the plas-
monic substrate is covered by the continuously injected protein IgG.
Fig. 5c shows the dual-wavelength diffraction patterns of 3 different
plasmonic pixels located on the same substrate, which are acquired
simultaneously by our lensfree on-chip imager before (at time, t0),
and after (at time, tf) the binding events. This simultaneous detection
capability of our biosensing platform is very important for high-
throughput and multiplexed screening applications. Fig. 5d shows
the variation in the intensity ratio of these diffraction image pairs
over 80 minutes of association phase (see the Methods section for
protein binding analysis). At each time point, three different sensor
elements (separated by 1 mm) have very similar intensity responses
and binding kinetics indicating that our hand-held device could
operate uniformly over a large field-of-view. To validate our lensfree
biosensing results, we also measure the peak wavelength of the plas-
monic resonance before and after the IgG injection using an optical
spectrum analyzer. Fig. 5d inset displays the amount of the spectral
shift between injection start and stop times (80 minutes duration),
providing ,6 nm peak wavelength shift for these 3 different plas-
monic pixels (see Supplementary Fig. 4). It is important to note that
the same target analyte that flows over different pixels yields the same
wavelength shift and a comparable change in our lensfree intensity
ratio, confirming robust detection of protein complexes using our
platform.
The biomolecular interactions between the target protein IgG and
the immobilized protein A/G can be modeled with the following
differential equation18.
d IgG{A=G½ =dt~ka IgG½  A=G½ {kd IgG{A=G½  ð1Þ
For the spectrum based biosensing measurements, the change rate of
the peak wavelength shift, dDl/dt, is directly related to the formation
of the protein complex [IgG 2 A/G]. Therefore, Equation 1 can be
integrated to determine the association rate equation18.
Dlt~ka IgG½ Dlmax 1{e {ka IgG½ zkdð Þt
 .
ka IgG½ zkdð Þ ð2Þ
where Dlmax is the maximum peak wavelength shift when all the
available binding sites are occupied and Dlt is the peak wavelength
shift from the initial peak wavelength at time t. This provides the
relation between the peak wavelength shift of the plasmonic chip and
the binding events as follows:
Dlt~Dl0 1{e
{ka IgG½ zkdð Þt
 
ð3Þ
where Dl0 5 (ka[IgG]Dlmax)/(ka[IgG] 1 kd).
Fig. 5b shows the amount of peak wavelength shift from its initial
position (just before the IgG insertion) obtained by an optical spec-
trum analyzer in real-time from a single plasmonic pixel during the
Figure 3 | Deep-UV Lithography based high-throughput fabrication of plasmonic nanohole arrays. (a) Photography of the wafer after deep-UV
and dry etching steps. (b) Single plasmonic chip containing eight plasmonic pixels. (c) SEM image of the nanohole array with a hole diameter of 200 nm
and an array period of 600 nm. (d) Fabrication steps of the nanohole arrays on free-standing silicon nitride membrane.
www.nature.com/scientificreports
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association phase of IgG. Based on the functional form presented in
Equation 3, we perform an exponential fit on this experimental spec-
trum data, which provides:
Dl~6:448 1{e{0:0005333t
  ð4Þ
Following the same strategy, for our lensfree on-chip biosensor, the
change in the IR can be related to the amount of biomolecular events
as follows:
IRt~IR0 1{e
{ka IgG½ zkdð Þt
 
ð5Þ
Thus, similar to Equation 4, we can obtain an exponential fit to our
lensfree experimental data yielding:
IR~0:10188 1{e{0:0005685t
  ð6Þ
Equations 4 and 6 reveal that two independent experiments (one
using an optical spectrum analyzer and the other using our dual-
wavelength lensfree sensor) yield similar exponential constants,
0.0005333 and 0.0005685, respectively.
Methods
The presented biosensing platform relies on multiple hardware and software sub-
components as detailed in the following subsections:
Fabrication of plasmonic substrates. Our fabrication process based on a deep-UV
lithography method is illustrated in Fig. 3d. We start the fabrication process with a
500-mm-thick silicon wafer that is coated with 100 nm-thick nitride films on both
sides. We first perform UV lithography to pattern the nanohole arrays with a Stepper
(ASML S500/300 DUV). We then develop the photoresist and etch through the top
silicon nitride layer to manufacture nanohole arrays using Plasma Therm 790 RIE/
PECVD with SF6 and Ar gases. We remove the remaining residues on the silicon
nitride surface by oxygen plasma cleaning. Following that, we pattern a 750 mm 3
750 mm window at the bottom silicon nitride layer through photolithography
performed on 2 mm thick positive photoresist (MicropositTM S1818TM) using a SUSS
Mask Aligner (MicroTec MA/BA6). Following the development of the photoresist
layer, we completely remove the silicon nitride layer within the transferred patterns at
the backside of the wafer. We then immerse the chip in KOH solution in order to
create freestanding silicon nitride membranes. We finally deposit Ti layer (adhesion
layer, 5 nm thick) andAu layer (125 nm thick), providing plasmonic nanohole arrays
without the need for a lift-off process. Each plasmonic biosensor pixel has a
dimension of 100 mm 3 100 mm, consisting of nanohole arrays each with a diameter
of 200 nm and a period of 600 nm.
Assembly of microfluidic system. To build microfluidic channels over nanohole
arrays, our plasmonic substrate is bonded to 4 layers of optically clear polyolefin film
(,50 mm thick) that is patterned with a cutting plotter from Graphtec (see
Supplementary Fig. 1). The assembled microfluidic chip has a channel height of
,100 mm and a flow chamber size of 4 mm 3 4 mm, which is used to perform leak-
free and low dead-volume flow experiments.
Sensitivitymeasurements.Test solutions are prepared by dissolving 0.37546 0.0002
grams of sucrose (Molecular weight: 342.2 g/mol) in 1.00 mL volume of Deionized
(DI) water, providing a 1.10 mol/L stock solution of sucrose 1.10 M. Such solution is
then further diluted with DI water at different concentrations, ranging from 0.055 to
1.10 mol/L, corresponding to refractive indices of 1.3356 to 1.3860, measured with a
refractometer (ATAGO PAL-series). These liquid samples are then used to evaluate
the sensitivity of our biosensing platform.
Spectroscopic analysis. For biodetection experiments based on the peak wavelength
shift of plasmonic modes, we mount our samples onto a Nikon Eclipse-Ti inverted
microscope which is fiber coupled to an optical spectrometer (SpectraPro 500i
spectrometer) and obtain the spectra under a normally incident white light
illumination.
Protein detection experiments. Initially, a 100 mg/mL protein A/G solution
(recombinant fusion protein with protein A and protein G binding sites dissolved in
phosphate buffered saline (PBS) 13, pH 7.4) is incubated on a freshly cleaned
plasmonic substrate for 20 minutes. Following the PBS wash of the chip 3 times, the
substrate is rinsed with DI water and dried with Nitrogen. A thin layer (,3 nm) of
protein A/G forms on the gold surface by physisorption12. This substrate is then
integrated with the microfluidic system, followed by the injection of a PBS solution
through the channel. Once the plasmonic sensor response is stabilized, we inject
Human IgG protein with an injection rate of ,10 mL/minute for 80 minutes,
achieving,12.5 picomoles per minute (Molecular Weight: 160 kDa, Concentration:
200 mg/mL), exhibiting an association phase of IgG onto the A/G proteins. Finally,
PBS is injected, which removes the excess IgG proteins that do not bind to the A/G
proteins. As a result of this association phase, an,8 nm thick bilayer of protein A/G
and antibody IgG complex is formed on the gold surface, and the binding events are
detected in real-time by our on-chip sensing platform. During the binding of IgG
antibody with the A/G proteins, the number of IgG molecules increases within the
,8 nm thick film. At the end of the experiment, when the available binding sites are
occupied by the IgG antibody, the optical response of the plasmonic sensor saturates.
Binding analysis of protein-protein interactions. Binding kinetics analysis of
protein A/G and IgG can be summarized in two sequential steps: (i) In the association
phase, IgG antibody protein is flowed over the sensor surface that is already
functionalized with protein A/G, creating a protein complex, IgG 1 A/GR
[IgG 2 A/G]. This binding process depends on the association constant (ka, 3.110x
105 M21s21) that demonstrates the predisposition of the small molecules to form
larger composites. (ii) In the dissociation phase, only a buffer is flowed over the
Figure 4 | Quantification of sucrose solutions at different concentrations
and refractive indices using our computational plasmonic biosensing
platform on a microfluidic chip. (a) Spectral response of the plasmonic
sensors under various concentrations of sucrose samples, ranging from
0.055 to 1.1 mol/L. Analysis of (b) the peak wavelength shift in the
plasmonicmode determined from the optical spectrometer measurements
and (c) the corresponding intensity ratio analysis determined using the
dual-wavelength lensfree images (error bar at each data point corresponds
to the measurements obtained from 3 different samples). Figure inset:
Zoomed version of the lower concentration sucrose measurements to
demonstrate the detection limit, shown with a red line.
www.nature.com/scientificreports
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surface, where the protein complex on the surface is detached to give free individual
proteins, i.e., [IgG 2 A/G]R IgG 1 A/G. This removal process depends on the
disassociation constant (kd, 10x 1026 s21) that measures the affinity of larger objects
to separate reversibly into smaller components. The dissociation constant for Protein
A/G andHuman IgG antibody is kd, 10x 1026 s21 19, indicating that the composite is
highly stable once it is formed and a minimum amount of IgG will remain unbound.
These binding events aremonitored through our lensfree plasmonic sensing platform
and used to further analyze protein-protein interactions, e.g., kinetics and
thermodynamic parameters and concentration, as commonly performed in SPR
literature19.
Dual-color lensfree imaging set-up. In order to record the diffraction patterns of
plasmonic pixels, we designed a lensfree imaging platform using a CMOS imager
(IDS, model: UI-1481LE, 5 Megapixel with 2.2 mm pixel size), two LEDs (Digikey,
models: 1125-1088-ND and 751-1211-ND, 820 and 880 peak wavelengths, 28 nm
and 40 nm bandwidth, respectively) that are positioned at D 5 11 mm lateral
spacing, and one button battery (3V Lithium Renata CR 2032). These parts are then
inserted into a mechanical housing that is designed in Inventor (Autodesk) and
manufactured using a 3D printer (Elite, Dimension). In this imaging geometry, LED
source to plasmonic chip (h1, 6.7 cm) and substrate to sensor array distance (h2,
3 mm) determine the center-to-center distance between the dual diffraction patterns
(d). In this current device, the center-to-center LED separation distance,D 5 11 mm
provides a diffraction pattern separation of d 5 0.5 mm based on the ratio of h1/h2
(see Supplementary Fig. 2 for various d and D combinations). Once the plasmonic
chip is inserted into our portable device, the constituting components are
mechanically aligned in the compact unit for subsequent biosensing experiments.
Digital processing of lensfree diffraction images. We start the digital analysis of
lensfree images by spatially localizing the centroids of dual-wavelength diffraction
patterns. In these images, dual diffraction patterns for each plasmonic pixel are
determined by assigning two neighboring regions of interest (ROIs) to a single
plasmonic pixel. The total transmission signal for each ROI is then calculated by
summing up the pixel photon count values over an area of 2003 200 pixels. Based on
this calculation, for each dual-wavelength diffraction pattern, the total transmission
signal of the ROI illuminated by 880 nm LED (I880) is divided by the signal of the ROI
illuminated by 820 nm LED (I820) to calculate an IR per plasmonic pixel:
IR~I880=I820
These measured IR values are used to quantify the binding events occurring in the
vicinity of the plasmonic chip (see e.g., Equation 6). For a series of lensfree frames, the
same ROIs are used for every plasmonic pixel on the substrate, where the IR values
were plotted against the number of frames to monitor the protein-protein binding
interactions over time. In this proof-of-principle demonstration, the intensities of the
two LEDs were not the same. The one at 820 nm is brighter than the one at 880 nm,
which results in an intensity difference between the two diffraction patterns detected
by the CMOS imager (Fig. 2b). Our ratiometric analysis eliminates the contributions
from such mismatches between the two LEDs.
Refractive index sensitivity (RIS) analysis. RIS is used to calculate the refractive
index change of the surrounding medium based on the ratio of the change in the
resonance wavelength of the plasmonic mode to the change in the refractive index of
themedium (RIS5Dl/Dn). For the nanohole array used in this work, wemeasure the
transmission signals of the bare nanohole array (lresonance,air 5 647 nm) and the
nanohole array embedded in DI-water (lresonance,water 5 852 nm), providing a
resonance shift of 205 nm. This results in an RIS value of 621 nm/RIU. For
spectrometer based measurements, Dn of target samples can then be calculated by
dividing Dl to the RIS value, which is Dn 5 Dl/RIS.
For our lensfree sensing approach, RIS is defined as the ratio of the change in the
diffraction pattern intensity to the change in the refractive index of the medium, i.e.,
RIS 5 DIR/Dn. In our platform, we obtain the intensity ratio for the nanostructures
measured in DI-water (IRWater 5 1.26468) and in 1.1 mol/L sucrose solution
(IRSucrose 5 2.19426), yielding an intensity ratio change of 0.92958. This provides an
RIS value of 17.53924/RIU. Dn of the target samples can then be calculated by
dividing DIR to the RIS value, i.e., Dn 5 DIR/RIS.
Figure 5 | Monitoring of binding kinetics of protein/protein interactions. (a) Schematic illustration of IgG and A/G protein interactions on the
plasmonic chip, containing 3 sensors (A, B, C), integrated with amicrofluidic chamber. (b) Exponential fit to the real-timemeasurement results obtained
by an optical spectrum analyzer. (c) Lensfree diffraction patterns of the nanohole arrays formed by dual LED illumination before (to) and after (tf) the
binding of the protein IgG on the surface of the plasmonic chip containing 3 sensors, covered with protein A/G. (d) Exponential fit to our lensfree dual-
wavelength measurement results. Figure inset: The validation of lensfree biosensing through optical spectrometer measurements performed before and
after the IgG binding, providing the same amount of peak wavelength shift (,6 nm) for 3 different plasmonic sensors.
www.nature.com/scientificreports
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Conclusion
We demonstrated a microfluidics based biosensing platform that
combines large-scale plasmonic microarrays with dual-wavelength
lensfree on-chip imaging for multiplexed and label-free monitoring
of binding events over a large field-of-view. This integrated biosen-
sing platform, weighing 40 grams with 8.8 cm in height, utilizes a
CMOS imager to record the diffraction patterns of plasmonic nano-
apertures located at the bottom of a micro-channel under simultan-
eous illumination by two different color LEDs located spectrally at
the right and left sides of the plasmonic mode. In this approach,
variations in the refractive index of the medium surrounding the
plasmonic nanohole arrays shifts the plasmonic mode of these nano-
structures, which enhances the transmission signal of one of the
diffraction patterns and decreases the transmission signal of the
other one. These acquired images are then processed through
the use of a ratiometric digital analysis method. Using the presented
plasmonic biosensor, we successfully monitored the real-time bind-
ing kinetics of protein A/G and protein IgG interactions. We also
introduced a deep UV lithography based fabricationmethod, rapidly
creating thousands of plasmonic nanostructures at low cost. This
provides a timely solution to the fabrication challenge of large-scale
plasmonic arrays that can be simultaneously screened with large
field-of-view imaging systems. Our plasmonic biosensing platform
would be highly advantageous for real-time and high-throughput
analysis of biomolecular interactions at resource-poor settings.
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